Short Interest in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Expands By 76.1%

Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Free Report) saw a significant growth in short interest in May. As of May 29th, there was short interest totaling 13,903 shares, a growth of 76.1% from the May 14th total of 7,893 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 24,005 shares, the short-interest ratio is presently 0.6 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded Alaunos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Get Alaunos Therapeutics alerts:

Check Out Our Latest Stock Analysis on Alaunos Therapeutics

Alaunos Therapeutics Price Performance

Alaunos Therapeutics stock traded up $0.02 during mid-day trading on Monday, hitting $2.28. 10,993 shares of the company were exchanged, compared to its average volume of 18,571. The business’s 50 day simple moving average is $2.63 and its two-hundred day simple moving average is $2.99. The company has a market capitalization of $55.68 million, a P/E ratio of -1.07 and a beta of -1.07. Alaunos Therapeutics has a 12-month low of $1.67 and a 12-month high of $6.20.

Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.59) earnings per share for the quarter.

Institutional Investors Weigh In On Alaunos Therapeutics

A hedge fund recently bought a new stake in Alaunos Therapeutics stock. HRT Financial LP acquired a new position in shares of Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 12,602 shares of the company’s stock, valued at approximately $40,000. HRT Financial LP owned about 0.54% of Alaunos Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 27.72% of the company’s stock.

About Alaunos Therapeutics

(Get Free Report)

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.

Read More

• Five stocks we like better than Alaunos Therapeutics
• These 5 Companies Just Made a Massive Bet on Themselves
• 5 Stocks Built to Thrive in a Higher-for-Longer Economy
• RH’s Strong Q1 Still Leaves Investors With One Big Question
• Iran Ceasefire or Not, These 3 Companies Could Win

Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.